Dr Traina on Integrating T-DXd and Biomarkers Into Early-Stage HER2-Positive Breast Cancer Care
Image supplied with the source report: Onclive.

Tiffany A. Traina, MD, FASCO, discusses incorporating T-DXd and biomarkers into early-stage HER2-positive breast cancer treatment.

Source disclosure

This is a source-linked briefing. Read the original report from Onclive .

Health us Onclive